Present Status of Therapeutic Apheresis in Japan: Survey Report

Shimizu, Masaru; Tsuda, Hiroshi; Sanaka, Tsutomu; Ide, Koki

doi:10.1111/j.1744-9987.1998.tb00100.x

Cited by 14 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of the anticoagulant drug nafamostat mesilate was reported only in the Asian region and only for one patient. As noted in the Japanese Registries (6,7), this drug is widely used in a large number of centers for anticoagulation. Of all patients, 66.2% were reported as taking no steroids or immunosuppressives for their therapy and nearly one‐fourth (23.7%) of the patients were on steroids only.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Apheresis Technologies and Clinical Applications: The 2005 International Apheresis Registry

Malchesky¹,

Koo

Roberson

et al. 2007

Ther Apher Dial

View full text Add to dashboard Cite

The developments in apheresis technologies and techniques and their clinical applications worldwide are technologically, sociologically, and economically motivated. In past apheresis surveys the statistics have highlighted both the differences by geographic region in clinical practice and in the types of technologies utilized. While a national view of apheresis is very important, an international view may be more representative overall of this therapeutic modality than national results that are highly dependent on the local economics and the available technologies. These regional differences have provided a basis for scientific and clinical assessment of these apheresis technologies and their clinical outcomes, and have impacted the marketing and business developments of new technologies worldwide. The results of the International Apheresis Registry for 2005 reporting from 22 centers on 5 continents are presented. The survey collected data exclusively via a secure internet website on 1133 patients for a total of 6501 treatments. Unlike our prior registries, information on stem cell infusions was gathered. Information gathered included patient demographics, medical history, treatment diagnoses, treatment specifics (type, methodology, access type, anticoagulants, drugs, and equipment usage), side-effects, clinical response, and payment provider. As in the prior International Apheresis Registries for 1983, 2000, and 2002 the survey results highlight the regional differences in apheresis usage and treatment methodologies, indicating that an international overview of apheresis may be more representative of the impact of this therapeutic modality.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Japan, with a population of 125 million, reported for 1995 on 164 centers (11.6%) for 1961 patientswith 15 670 procedures (estimated 26% of all procedures) on 100 disease types (6). The top three disease categories treated were: endocrine, metabolic, nutrition and immunologic; gastrointestinal; and neurological and sensory.…”

Section: Discussionmentioning

confidence: 99%

Apheresis Technologies and Clinical Applications: The 2005 International Apheresis Registry

Malchesky¹,

Koo

Roberson

et al. 2007

Ther Apher Dial

View full text Add to dashboard Cite

show abstract

“…Much is known about therapeutic apheresis (TA) and its value as a treatment modality for selected disorders in countries like Canada [1], France [2], the United States [3], and Japan [4], which have organized national registries and multicenter study groups to determine the activity in TA and to help plan randomized clinical trials and resolve problems regarding appropriate clinical applications. In the Philippines, there is still a paucity of information regarding its use, which has grown steadily, but slowly, in the past decade.…”

Section: Introductionmentioning

confidence: 99%

Apheresis in the Philippines

Narciso

2005

J of Clinical Apheresis

View full text Add to dashboard Cite

This is a retrospective study of 131 patients who underwent 479 therapeutic apheresis (TA) procedures at St. Luke's Medical Center, in the Philippines, from 1994 to 2003. Diseases were classified according to indication categories using the American Society for Apheresis (ASFA) guidelines. Seventy-eight percent of the patients belonged to ASFA Category I, 14% to Category II, 8% to Category III, and none in Category IV. The most common indication was for neurological disorders (62%), mainly acute inflammatory demyelinating polyneuropathy (49%) and myasthenia gravis (40%). The remaining disease groups were hematologic (25%), renal and metabolic (8%), and autoimmune and rheumatic diseases (5%). Oral corticosteroids are the preference of many for the treatment of CIDP, being much less expensive than IVIG infusion or TA. Favorable response is noted in the use of the latter to prevent kidney transplant rejection through antibody removal among pre-sensitized patients before transplantation. Complete recovery was seen in 2 of 4 patients with acute hepatic failure. The negative outcome of controlled studies in the literature has limited our utilization of TA for the treatment of systemic lupus erythematosus. Immunoadsorption for idiopathic thrombocytopenic purpura has not been performed locally due to the unavailability and prohibitive cost of affinity columns. Factors affecting the practice of TA in our country are cited. Organization of a multicenter study group and an apheresis national registry may lead to a better future of TA in the Philippines.

show abstract

“…Moreover, adverse events that occurred while LCAP was performed were all not specifi c to LCAP but were they adverse events generally observed during extracorporeal therapy. [9][10][11][12][13] …”

Section: Safety Of Lcap Therapymentioning

confidence: 99%